SCHEMBL20745902

SCHEMBL20745902

O=Cc1ccnc(-c2cccc(C(F)F)c2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
KMT2A Q03164 2/20 0.41
MPI P34949 1/20 0.41
NOTUM Q6P988 1/20 0.39
MAPKAPK2 P49137 1/20 0.34
SLC10A1 Q14973 1/20 0.33
GRIN2B Q13224 8/20 0.33
GRIN1 Q05586 5/20 0.33
CYP1A2 P05177 3/20 0.33
CYP3A4 P08684 3/20 0.33
PIK3CD O00329 2/20 0.33
PIK3CA P42336 2/20 0.33
ALOX15 P16050 1/20 0.33
LMNA P02545 2/20 0.32
TP53 P04637 1/20 0.32
CYP2C9 P11712 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MEN1 O00255 1/20 0.32
USP2 O75604 1/20 0.32
CYP2D6 P10635 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22320609 0.82 KMT2A (0.47) ALDH1A1KMT2AMPINOTUMSMN1; SMN2
SCHEMBL2666241 0.78 RXRA (0.44) NOTUMMAPKAPK2GRIN2BGRIN1CLK4
SCHEMBL18002781 0.76 KMT2A (0.52) ALDH1A1KMT2AMPISMN1; SMN2MEN1
SCHEMBL20745959 0.75 GRIN1 (0.47) NOTUMGRIN2BGRIN1PIK3CDPIK3CA
SCHEMBL18839235 0.74 SYK (0.32) ALDH1A1NOTUM
SCHEMBL30147514 0.74 SYK (0.32) ALDH1A1NOTUM
SCHEMBL16180291 0.74 CLK4 (0.62) ALDH1A1KMT2AMPICYP1A2CYP3A4
SCHEMBL20745651 0.72 SMN1; SMN2 (0.49) ALDH1A1KMT2ANOTUMMAPKAPK2GRIN2B
SCHEMBL4585500 0.72 CCR1 (0.46) ALDH1A1KMT2AMPISLC10A1
SCHEMBL30132148 0.70 ALDH1A1 (0.50) ALDH1A1KMT2AMPISLC10A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112739343-A Macrocyclic MCL-1 inhibitors and methods of use 艾伯维公司 2021-04-30 CN disclosed
US-20200255451-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE ABBVIE INC (US) 2020-08-13 US disclosed
EP-3668504-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE AbbVie Inc. (US) 2020-06-24 EP disclosed
WO-2019035914-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE ABBVIE INC. (US) 2019-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200255451-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE MCL1, BCL2A1, BCL2L10 ALDH1A1 647/4885KMT2A 1375/4885MPI 2637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.